Simulations Plus And University Of Bath Awarded FDA Grant
Portfolio Pulse from Benzinga Newsdesk
Simulations Plus, in partnership with the University of Bath, has been awarded an FDA grant to develop an enhanced, validated dermal PBBM/PBPK model. This model aims to inform product development and bioequivalence decisions, marking a significant advancement in the field.
March 05, 2024 | 1:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Simulations Plus has been awarded an FDA grant in partnership with the University of Bath to develop a dermal PBBM/PBPK model, which is expected to enhance product development and bioequivalence decisions.
The FDA grant to Simulations Plus for developing a dermal PBBM/PBPK model signifies recognition and support from a regulatory body, potentially leading to increased credibility and future opportunities in the pharmaceutical and healthcare sectors. This development is likely to be viewed positively by investors, as it could enhance the company's product offerings and market position, thus potentially leading to a short-term positive impact on the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90